Baird Maintains Outperform on Reata Pharmaceuticals, Raises Price Target to $173
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Brian Skorney maintains an Outperform rating on Reata Pharmaceuticals (NASDAQ:RETA) and raises the price target from $85 to $173.
July 31, 2023 | 7:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Reata Pharmaceuticals' price target has been raised from $85 to $173 by Baird, maintaining an Outperform rating.
The news of Baird raising the price target for Reata Pharmaceuticals from $85 to $173 while maintaining an Outperform rating is likely to have a positive impact on the stock. This is because it signals the analyst's increased confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100